18.75
+0.21%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Tailin Bioengineering Co
Its shares trade on Shenzhen under the ticker 300813.SZ. It has been listed since 14 January 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥334.4m and net income of CN¥16.5m. At that date it held total assets of CN¥959.3m and shareholders' equity of CN¥804.3m.
Zhejiang Tailin Bioengineering Co., Ltd. engages in the research, development, manufacturing, and sales of pharmaceutical equipment, including microbial detection and control technology system products, as well as organic substance analysis instruments. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2020-01-14. The firm's main business is the research, development, manufacturing and sales of microbial detection and control technology system products, organic substance analysis instruments and other pharmaceutical equipment. Specific products include various consumables, instruments and equipment, which can be used alone or in combination for the production and quality of sterile drugs. The application areas that can be expanded include medical and health, food safety, disease prevention and control, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 14 Jan 2020
- Employees
- 836
- Website
- tailingood.com ↗
Leadership
Pay as last reported
- Mr. Dalin YeChairman of the Board, General Manager, since 2015CN¥606,000
- Mr. Xingyue YeChief Financial Officer, Secretary of the BoardCN¥634,200
- Mr. Zhilin ShenDeputy General Manager, Director, since 2015CN¥919,000
- Mr. Xinqun XiaDeputy General Manager, Director, since 2015CN¥1.1m
- Mr. Xiaolu NiDirector
- Mr. Ming DongIndependent DirectorCN¥60,000
- Mr. Guowei LiIndependent Director
- Mr. Ya NiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Tailin Bioengineering employs 836 full-time employees in Hangzhou, China.
- The company's microbial detection and control technology systems are used in sterile drug production quality control.
- Zhejiang Tailin's organic substance analysis instruments serve medical and health sectors globally.
Weaknesses
- Zhejiang Tailin's business is limited to pharmaceutical equipment without diversification into other sectors.
- The company's products are primarily distributed within domestic market and overseas markets.
- Zhejiang Tailin's IPO was on 14 January 2020, which may affect long-term financial stability.
Opportunities
- Zhejiang Tailin can expand into food safety and disease prevention control application areas.
- The firm can leverage its microbial detection systems for biosecurity and environmental protection sectors.
- Zhejiang Tailin's products can be used in laboratory animals and inspection and quarantine applications.
Threats
- Zhejiang Tailin faces competition from other pharmaceutical equipment manufacturers in China.
- The company's reliance on domestic market distribution could be impacted by trade policies.
- Zhejiang Tailin's focus on sterile drug production may limit market growth opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.